Viewing nowCombinationRinadiem Met Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.

MFDS item code 202400388 · Approved 2024.02.22 · Insurance code 642707560
Improvement of blood glucose control in type 2 diabetes
This medication is used to assist blood glucose control in patients with type 2 diabetes who are also following dietary and exercise regimens. By administering Linagliptin and Metformin together, it helps manage blood glucose more effectively.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this 5/1000 mg extended-release tablet once daily. Patients taking this 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment The initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate, if necessary. When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be equivalent to the current doses of linagliptin and extended-release metformin hydrochloride. As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically during treatment with this medicine. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) with creatine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dosage adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45mL/min or estimated glomerular filtration rate (eGFR) decreases to below 45mL/min/1.73m2, this medicine must be discontinued immediately.
This medication may cause severe lactic acidosis or hypoglycemia, therefore caution is required. Individuals with an allergy to any of the ingredients or other components should not use this medication. It is not indicated for patients with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. Patients with severely impaired kidney function or in a state where acute kidney damage is anticipated should not use this medication. Administration should be avoided during acute illnesses affecting kidney function, such as dehydration, severe infections, severe injuries, or acute myocardial infarction. Patients with very poor cardiac function or severe pulmonary dysfunction should exercise caution when using this medication. Patients with liver dysfunction or severe gastrointestinal disorders should preferably avoid this medication. It should not be used in cases of acute or chronic alcohol intoxication. Administration should be avoided in patients with very poor nutritional status or states of starvation or frailty. Patients with acute and unstable heart failure, pregnant women at risk of placental insufficiency or pre-eclampsia, or those with a history of myocardial infarction should not use this medication. Due to the risk of hypoglycemia, careful dose adjustment is necessary, especially when used in combination with sulfonylureas or insulin. Although lactic acidosis is very rare, it is a serious complication that requires immediate consultation with a doctor in cases of worsening kidney function, cardiopulmonary disease, or sepsis. Regular monitoring of kidney function is recommended, especially for elderly patients or those with deteriorated kidney function. If iodinated contrast agents are used for imaging studies, it is necessary to discontinue this medication before and after the exam and check the kidney function status. It is advised to temporarily stop taking this medication for a certain period before and after surgery. If symptoms of acute pancreatitis or bullous skin disease occur, promptly inform a physician and discontinue this medication. Long-term use may lead to vitamin B12 deficiency; therefore, regular blood tests are recommended. This medication should be swallowed whole without chewing or crushing, and some tablet coatings may be excreted in the stool, which is normal. There may be interactions when taken with other medications, especially those affecting kidney function, so caution is necessary when used in combination. Use during pregnancy or breastfeeding is not recommended, and those planning to become pregnant should consult healthcare professionals. Safety for pediatric use has not been established, hence it should not be used in children. For the elderly, the possibility of kidney function decline is higher, thus starting at the lowest dosage and regularly checking kidney function is advised. In case of overdose, there is a risk of lactic acidosis, and immediate hospital treatment is required; hem dialysis may be necessary. Keep this medication out of the reach of children, and store it away from moisture.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.
Yellow, double convex, oval extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.